APGE241220P80000
- 0.00
- 0.000.00%
Apogee Therapeutics Newsroom
Guggenheim Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110
Apogee Therapeutics Price Target Raised to $110 From $95 at Guggenheim
Express News | Apogee Therapeutics Inc : Guggenheim Raises Target Price to $110 From $95
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
CCORF Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $89
Apogee Therapeutics Initiated at Buy by Canaccord Genuity
Canaccord Genuity Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $89
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100
Express News | Apogee Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results
Apogee Therapeutics | 8-K: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
Apogee Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Apogee Therapeutics Inc: Net Loss for Q3 of 2024 Was $49.0 Mln
Express News | Apogee Therapeutics Inc: $754 Mln Cash, Cash Equivalents and Marketable Securities With Runway Into 2028
Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
BioSpace Announces 2025 Best Places to Work in Life Sciences Winners
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating